MarketCap
Facebook
X
Telegram
Alpine Immune Sciences Operating Cycle | ALPN
Annual Operating Cycle Alpine Immune Sciences
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1.73 | 154 | 195 | - | 144 | 123 | 27 | - | - | - | - | - | - |
Annual performance
Select metrics to display
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 195 | 1.73 | 107 |
Quarterly Operating Cycle Alpine Immune Sciences
| 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1.36 | - | 2.29 | 5.05 | 5.15 | - | 9.26 | 12.5 | 84.1 | - | 243 | 288 | - | - | 1.26 K | 315 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Quarterly performance
Select metrics to display
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 1.26 K | 1.36 | 202 |
Operating Cycle of other stocks in the Biotechnology industry
| Issuer | Operating Cycle | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Outlook Therapeutics
OTLK
|
642 | $ 0.48 | 4.34 % | $ 16.7 M |  USA |
 |
uniQure N.V.
QURE
|
53.2 K | $ 24.64 | 8.5 % | $ 1.42 B |  Niderland |
 |
Ultragenyx Pharmaceutical
RARE
|
37.7 | $ 16.7 | 3.44 % | $ 1.65 B | USA |
 |
Sarepta Therapeutics
SRPT
|
12.3 K | $ 16.67 | 1.4 % | $ 1.67 B | USA |
 |
REGENXBIO
RGNX
|
395 | $ 8.57 | 11.38 % | $ 442 M | USA |
 |
Rigel Pharmaceuticals
RIGL
|
221 | $ 44.17 | 0.58 % | $ 794 M | USA |
 |
SELLAS Life Sciences Group
SLS
|
242 | $ 8.41 | 0.5 % | $ 917 M | USA |
 |
I-Mab
IMAB
|
15.5 | - | - | $ 866 M |  China |
 |
Tenax Therapeutics
TENX
|
1 K | $ 1.7 | 0.3 % | $ 66.7 M | USA |
 |
Alexion Pharmaceuticals, Inc.
ALXN
|
12.8 | - | - | $ 40.3 B | USA |
 |
Midatech Pharma plc
MTP
|
245 | - | -18.52 % | $ 27.3 M |  Britain |
 |
Affimed N.V.
AFMD
|
31.4 | - | -34.95 % | $ 21.5 M |  Germany |
 |
AnPac Bio-Medical Science Co., Ltd.
ANPC
|
152 | - | -1.58 % | $ 28.1 M | China |
 |
Celyad Oncology SA
CYAD
|
64.4 | - | - | $ 12.5 M |  Belgium |
 |
Seer
SEER
|
343 | $ 1.61 | -0.31 % | $ 88.9 M | USA |
 |
Stoke Therapeutics
STOK
|
7.52 | $ 27.75 | 1.98 % | $ 1.64 B | USA |
 |
Sutro Biopharma
STRO
|
22.4 | $ 10.25 | 0.79 % | $ 87.1 M | USA |
 |
Soligenix
SNGX
|
87.4 | $ 0.32 | 0.37 % | $ 1.66 M | USA |
 |
Teva Pharmaceutical Industries Limited
TEVA
|
959 | $ 43.19 | 1.85 % | $ 49.5 B |  Israel |
 |
China SXT Pharmaceuticals
SXTC
|
687 | $ 2.96 | 2.78 % | $ 2.01 M | China |
 |
Takeda Pharmaceutical Company Limited
TAK
|
334 | $ 20.83 | -0.38 % | $ 32.9 B |  Japan |
 |
Supernus Pharmaceuticals
SUPN
|
492 | $ 29.29 | 1.88 % | $ 1.65 B | USA |
 |
Galapagos NV
GLPG
|
149 | - | - | $ 1.83 B | Belgium |
 |
Teligent, Inc.
TLGT
|
167 | - | -13.85 % | $ 16.1 M | USA |
 |
Viela Bio, Inc.
VIE
|
174 | - | - | $ 2.91 B | USA |
 |
TG Therapeutics
TGTX
|
556 | $ 65.76 | 2.33 % | $ 9.49 B | USA |
 |
Aphria Inc.
APHA
|
156 | - | -0.45 % | $ 4.87 B |  Canada |
 |
Chiasma, Inc.
CHMA
|
19.9 | - | -6.00 % | $ 238 M | USA |
 |
Adamas Pharmaceuticals, Inc.
ADMS
|
252 | - | - | $ 376 M | USA |
 |
Cellect Biotechnology Ltd.
APOP
|
82.8 | - | 0.38 % | $ 12.9 M | Israel |
 |
AzurRx BioPharma, Inc.
AZRX
|
53.4 | - | 2.07 % | $ 34.4 M | USA |